Jennison Associates Portfolio holdings
Jennison Associates is the research-driven stock investing arm of PGIM, the asset management business of Prudential Financial. It started in 1969, through a predecessor company, managing growth stock accounts of large U.S. companies, mainly for large institutions, and Prudential bought it in 1985. Its growth stock investors believe that rising earnings and cash flow drive share prices, and it also runs long-only and long/short portfolios of global healthcare companies. It began advising mutual funds in 1990 and also manages bond portfolios, choosing investments through its own company-by-company research. Its clients include pension plans, public employee retirement systems, foundations and endowments.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SpaceX
SPCX
|
+$1.27B |
| 2 |
Sandisk
SNDK
|
+$674M |
| 3 |
Credo Technology Group
CRDO
|
+$476M |
| 4 |
Nebius Group N.V.
NBIS
|
+$452M |
| 5 |
Vertiv
VRT
|
+$420M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$1.98B |
| 2 |
Amazon
AMZN
|
+$1.25B |
| 3 |
Shopify
SHOP
|
+$1.08B |
| 4 |
Edwards Lifesciences
EW
|
+$1.07B |
| 5 |
Microsoft
MSFT
|
+$630M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 43.11% |
| 2 | Communication Services | 13.94% |
| 3 | Consumer Discretionary | 10.64% |
| 4 | Industrials | 9.08% |
| 5 | Healthcare | 8.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
101
Ameren
AEE
$31.4B
| $154M | 0.09% |
1,365,345
-44,221
| -3% | -$4.89M |
2013 Q2
52 quarters
|
|
102
East-West Bancorp
EWBC
$18B
| $153M | 0.09% |
1,186,619
-38,496
| -3% | -$4.73M |
2013 Q2
52 quarters
|
|
103
Xcel Energy
XEL
$52.3B
| $149M | 0.09% |
1,858,552
-62,931
| -3% | -$5.02M |
2015 Q1
45 quarters
|
|
104
Palvella Therapeutics
PVLA
$2.24B
| $147M | 0.09% |
960,619
+320,008
| +50% | +$38.8M |
2025 Q3
3 quarters
|
|
105
Eldorado Gold
EGO
$8.31B
| $147M | 0.09% |
4,716,829
-2,764,019
| -37% | -$90M |
2024 Q1
9 quarters
|
|
106
Element Solutions
ESI
$8.08B
| $147M | 0.09% |
3,069,033
+91,075
| +3% | +$3.78M |
2024 Q3
7 quarters
|
|
107
Markel Group
MKL
$24B
| $146M | 0.09% |
74,748
+3,304
| +5% | +$6.17M |
2023 Q1
13 quarters
|
|
108
PG&E
PCG
$28.6B
| $146M | 0.09% |
8,673,570
-268,954
| -3% | -$4.53M |
2020 Q4
22 quarters
|
|
109
RTX Corp
RTX
$268B
| $145M | 0.09% |
764,638
-614,160
| -45% | -$113M |
2014 Q4
46 quarters
|
|
110
Eastern Bankshares
EBC
$5.11B
| $145M | 0.09% |
6,514,253
-331,963
| -5% | -$6.74M |
2020 Q4
22 quarters
|
|
111
Protagonist Therapeutics
PTGX
$8.77B
| $141M | 0.08% |
1,151,681
+79,670
| +7% | +$8.32M |
2025 Q4
2 quarters
|
|
112
Lattice Semiconductor
LSCC
$16.9B
| $141M | 0.08% |
922,462
-450,122
| -33% | -$58.1M |
2025 Q3
3 quarters
|
|
113
General Motors
GM
$72.8B
| $141M | 0.08% |
1,822,937
-533,945
| -23% | -$42M |
2020 Q2
24 quarters
|
|
114
Wintrust Financial
WTFC
$10.4B
| $140M | 0.08% |
872,304
+23,659
| +3% | +$3.56M |
2013 Q2
52 quarters
|
|
115
DoorDash
DASH
$75.2B
| $138M | 0.08% |
+749,471
| New | +$124M |
2026 Q2
0 quarters
|
|
116
Solaris Energy Infrastructure
SEI
$4.48B
| $136M | 0.08% |
1,691,193
+511,457
| +43% | +$36.6M |
2025 Q2
4 quarters
|
|
117
Camden Property Trust
CPT
$9.8B
| $135M | 0.08% |
1,178,945
-27,909
| -2% | -$2.97M |
2024 Q3
7 quarters
|
|
118
Thermo Fisher Scientific
TMO
$259B
| $135M | 0.08% |
269,128
+30,726
| +13% | +$14.8M |
2025 Q2
4 quarters
|
|
119
Kontoor Brands
KTB
$4.25B
| $134M | 0.08% |
1,603,623
+378,252
| +31% | +$27.6M |
2019 Q3
27 quarters
|
|
120
Lincoln National
LNC
$7.96B
| $133M | 0.08% |
3,772,433
-50,719
| -1% | -$1.82M |
2025 Q2
4 quarters
|
|
121
Alliant Energy
LNT
$18.9B
| $131M | 0.08% |
1,713,259
-52,908
| -3% | -$3.85M |
2024 Q4
6 quarters
|
|
122
Scholar Rock
SRRK
$5.27B
| $130M | 0.08% |
2,358,587
-981,905
| -29% | -$47.4M |
2025 Q2
4 quarters
|
|
123
Lifestance Health
LFST
$5.38B
| $129M | 0.08% |
12,077,557
+1,848,756
| +18% | +$14.3M |
2023 Q1
13 quarters
|
|
124
Prologis
PLD
$122B
| $129M | 0.08% |
951,858
-462,885
| -33% | -$65.6M |
2019 Q2
28 quarters
|
|
125
Immunovant
IMVT
$7.25B
| $128M | 0.08% |
3,310,238
+113,533
| +4% | +$3.46M |
2025 Q4
2 quarters
|
|
Similar funds
Jennison Associates's Q2 2026 Portfolio in Review
As of Q2 2026, Jennison Associates held 641 positions worth $167B, up 15% from $145B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Jennison Associates withdrew a net $6.22B in Q2 2026, closing 74 positions and reducing 282 holdings. Its most notable exit was Gilead Sciences, an estimated $176M position sold in full.
By sector, the portfolio is most concentrated in Technology at 43% of assets, up from 39% a quarter earlier, followed by Communication Services and Consumer Discretionary.
Against the trend, Jennison Associates opened a new position in SpaceX worth $1.27B.
- Jennison Associates's largest Q2 2026 buy was SpaceX: 7,448,891 shares worth $1.27B.
- Jennison Associates added most to Credo Technology Group in Q2 2026, an estimated $476M increase.
- Jennison Associates's biggest Q2 2026 reduction was NVIDIA, cutting an estimated $1.98B.
- Jennison Associates fully exited Gilead Sciences in Q2 2026, selling an estimated $176M.
- Jennison Associates's ten largest holdings make up 45% of its $167B portfolio in Q2 2026.
- Jennison Associates opened 79 new positions and closed 74 in Q2 2026.
- Jennison Associates's portfolio value rose 15% quarter-over-quarter to $167B.
Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.